Eli Lilly and Company (NYSE:LLY) is set to channel $1 billion into expanding contract manufacturing operations in India, with the goal of supplying medicines produced in the country to international markets.
The U.S. drugmaker plans to position India as a key manufacturing base within its global supply network, according to details released Tuesday.
In addition to strengthening its production capabilities, Eli Lilly intends to broaden its presence in India by launching more therapies locally, including its Alzheimer’s drug donanemab.
The sizable investment highlights India’s rising role in the global pharmaceutical value chain, as multinational companies increasingly rely on the country for large-scale drug manufacturing and export operations.